Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entity is a **novel antisense transcript complementary to the ARHGEF1 gene**, likely belonging to the class of natural antisense RNAs (NATs). Antisense transcripts can modulate expression of their sense partner gene via transcriptional interference, RNA masking, or recruitment of chromatin-modifying complexes, but specific biological roles for this transcript have not been established[6][2]. ARHGEF1 itself encodes a RhoA-specific guanine nucleotide exchange factor implicated in lymphocyte migration and lymphoma progression[1][3][4][5]. This antisense RNA is annotated by Ensembl but is not a protein-coding therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to Rho guanine nucleotide exchange factor 1 (ENSG00000296972).